The association of TNF-a 308G/A polymorphism and diabetic nephropathy: a meta-analysis by Πάσχου, Ελένη
University of Thessaly  
Medical School 
 
 
Master In Science 
 
Methodology of Biomedical Research, Biostatistics and 
Clinical Bioinformatics 
 
Academic Year 2014 – 2015 
 
 
 
 
“The association of TNF-a 308G/A 
polymorphism and Diabetic Nephropathy. 
A meta-analysis” 
 
Supervisor: Prof.  Stefanidis Ioannis 
Department of Nephrology 
University Hospital of Larisa 
 
 
 
-  Eleni Paschou  - 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:30 EET - 137.108.70.7
2 
 
 
TABLE OF CONTENTS 
 
 
 
 
 
 
 
1. Abstract ………………………………………………………….. 3 
- Introduction 
- Purpose of the Study 
- Methods 
- Results 
- Conclusion 
 
2. Introduction …………………………………………………………… 4 
2.1 Epidemiology of Diabetic Nephropathy ……………………………  4 
2.2 Pathophysiology of Diabetic Nephropathy ……………………  4 
2.3 The role of Inflammatory Cytokines in Diabetic Nephropathy ……   5 
2.4 TNF-a and Diabetic Nephropathy …………………………………….. 5 
 
3. Methods …………………………………………………………… 6 
3.1 Identification and Eligibility of relevant studies …………………… 6 
3.2 Data extraction …………………………………………………… 6 
3.3 Statistical Analysis …………………………………………… 6 
 
4. Results …………………………………………………………………… 7 
4.1 Eligible Studies and study characteristics …………………………… 7 
4.2 Summary statistics …………………………………………… 12 
4.2.1. Meta-analysis A: Healthy Controls …………………………….. 12 
4.2.1.1. Sensitivity Analysis ……………………………………… 14 
4.2.1.2.Subgroup analysis ……………………………………… 15 
4.2.2. Meta-analysis B: Diseased Controls ……………………………… 18 
 
5. Conclusions …………………………………………………………… 21 
 
6. References …………………………………………………………… 22 
 
 
 
 
 
 
 
 
 
 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:30 EET - 137.108.70.7
3 
 
1. Abstract 
 
 
 
Introduction 
 
Diabetic nephropathy, an irreversible progressive kidney disease, represents 
the most common cause of end-stage renal disease in adults globally. The 
pathophysiology of the disease is multifactorial and remains unidentified, although 
extensive research in this field has revealed various underlying mechanisms. 
Inflammatory cytokines such as TNF-a have been suggested that participate 
fundamentally in the pathogenesis of renal insufficiency. 
 
Purpose of the study 
 
Several genetic variations of the promoter region of TNF-a such as 308 G/A in 
patients with diabetes mellitus and nephropathy have been studied. In this meta-
analysis we aim to examine the association between this polymorphism and the risk of 
diabetic nephropathy. 
 
Methods 
 
The electronic search of the Pubmed database literature that conducted until 
August 2015 revealed nine candidate-genome associated studies that examine the 
distribution of AA, AG and GG genotypes of the current polymorphism in cases and 
controls subjects. Due to the complexity of the pathophysiology observed in diabetic 
nephropathy, studies were divided into two subgroups: one with diseased controls and 
one with healthy controls. Thus, two different meta-analyses were performed. 
 
Results 
 
In studies with healthy controls, dominant model showed increased risk of 
diabetic nephropathy in A carriers (OR=1.45, 95% CI: 0.797-2.635). Heterogeneity 
was significant (PQ<0.01, I
2
=86.78%) and sensitivity analysis for studies in HWE showed 
further significant association (OR= 2.701, 95% CI: 1.089 – 6.701). Subgroup analysis 
produced increased risk of diabetic nephropathy for Asians but not for Caucasians. Meta-
analysis of studies with diseased controls showed no statistically significant association 
between TNF-a 308 G/A polymorphism and the risk of diabetic nephropathy. 
 
 
Conclusions 
 
The results suggest that the TNF-a 308 G/A polymorphism may be associated 
with an increased risk of nephropathy in Asians with diabetes mellitus compared to 
healthy individuals but not in Caucasians. Since the pathogenesis of the disease 
implicates several mechanisms, further large-scale genome associated studies are 
required in order to minimize potential bias and interpret those results correctly. 
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2. Introduction 
 
 
Diabetic nephropathy is a progressive kidney disease associated with diabetes 
mellitus type 1 and type 2, affecting kidney glomeruli, arterioles, tubules and 
interstitium. It is the most common cause leading to chronic kidney disease in adults, 
consisting a worldwide unsolved problem with unprecedented social and economic 
repercussions [1]. 
Gradually, diabetic nephropathy is characterized by the clinical triad of 
albuminuria, hypertension and reduction in glomerular filtration rate. The presence of 
microalbuminuria in a person with diabetes mellitus may progressively lead to end-
stage renal disease, requiring dialysis or kidney transplantation. In this context, 
microalbuminuria heralds the onset of a dramatically increased risk of death 
correlated with accelerated atherosclerosis and cardiovascular events [2]. 
 
2.1  Epidemiology of Diabetic Nephropathy 
 
Nephropathy affects around 30% of patients with type 1 diabetes and 20% of 
patients with type 2 diabetes [1]. Duration of diabetes is the major risk factor for the 
development of kidney disease. Men appear to be at a higher risk of developing 
nephropathy [3]. Ethnicity seems to be an important factor since there are studies 
supporting that South-Asians and African-Caribbeans are at higher risk [4, 5]. 
Early studies showed a 10-year survival after the onset of persistent 
albuminuria of 28% [6], but more recent statistics suggest dramatically improved 
prognosis in diabetic nephropathy (82% 10-year survival) due to advances in blood 
pressure therapy and renal replacement therapy. 
 
 
 
2.2  Pathophysiology of Diabetic Nephropathy 
In diabetic nephropathy, as in most diabetes-associated complications, the 
pathophysiology is multifactorial mostly because the involved molecular pathways 
constitute a wide and complex network of regulators. 
Pathophysiological events in diabetic nephropathy evolve a much more complex 
scenario with both genetic and environmental factors [7, 8]. In the classical view, 
renal damage results due  to metabolic and hemodynamic alterations that increase 
systemic and intraglomerular pressure. In these conditions, modification of molecules 
under hyperglycemic conditions – such as AGEs - play significant role in renal 
endothelial dysfunction.  It seems that the key mechanism in the etiology of diabetic 
nephropathy is subclinical inflammation observed in cellular and molecular level. In 
this direction, new potential targets are identified leading to the design of innovative 
anti-inflammatory therapeutic strategies. 
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2.3  The role of Inflammatory Cytokines in Diabetic Nephropathy 
A potential participation of inflammatory cytokines in the pathogenesis of diabetic 
nephropathy was suggested for the first time in 1991 when Hasegawa et al. [9] 
demonstrated that peritoneal macrophages cultured with glomerular basement 
membranes from diabetic rats produced significantly higher amounts of  tumor 
necrosis factor-alpha (TNF-α) and interleukin- (IL-) 1 than those cultured with 
glomerular basement membranes from normal rats. 
In general, renal cells are capable of synthesizing proinflammatory cytokines such 
as TNF-α, IL-1, and IL-6. These cytokines may induce a variety of effects on different 
renal structures [10], acting in a paracrine or autocrine way, that play a significant role 
in the development and progression of renal impairment. Mainly, cytokine effects in 
renal function and structure provoke the expression of different molecules, 
intraglomerular hemodynamic abnormalities, endothelial permeability and oxidative 
stress, alteration of extracellular matrix and glomerular basement membranes, 
apoptosis and necrosis  [11] resulting to the development of diabetic nephropathy. 
 
 
 
2.4  TNF-a and Diabetic Nephropathy 
Many clinical studies in patients with diabetic nephropathy have reported that 
serum and urinary concentrations of TNF-α are elevated compared to nondiabetic 
individuals or with diabetic subjects without renal failure. These concentrations 
increase concomitantly with the progression of diabetic nephropathy. Such findings 
indicate a potential relationship between the elevated levels of this inflammatory 
cytokine and the development and progression of chronic kidney disease in diabetes 
mellitus [12, 13].  
TNF-α codes by TNF gene located in chromosome 6q21 in the human 
leukocyte antigen (HLA) region class III [14]. It is mainly produced by monocytes, 
macrophages, and T cells but also intrinsic kidney cells [15-17] and it increases the 
release of other cytokines, chemokines, growth factors, and acute phase proteins [18]. 
Experimental studies in animal models of diabetes have showed that TNF-α protein 
and expression levels are enhanced in renal glomeruli and tubules [19-22]. 
TNF-α is a  pleiotropic cytokine that exerts multiple effects. It contributes to 
the development of diabetic nephropathy through several mechanisms. The most 
important are reduction of the glomerular blood flow and glomerular filtration rate. 
As a consequence, the disequilibrium between factors promoting vasoconstriction and 
vasodilation [23] such as endothelin- 1 and disruption of the glomerular filtration 
barrier lead to proteinuria [18]. Increased production of TNF-α can also arouse 
oxidative stress, through the activation of nicotinamide adenine dinucleotide 
phosphate (NADPH) in mesangial cells. Finally, TNF-α appears to have a direct 
apoptotic and cytotoxic effect on glomerular cells [11, 18, 24, 25]. 
Genetic variations in the promoter region may regulate TNF-a production. The 
most well studied TNF-a promoter variants are guanine (G) to adenine (A) 
substitutions in positions -238 and -308 [26]. It has been reported that TNF-a 308 G/A 
polymorphism is associated with the onset of obesity [27] and insulin resistance in 
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diabetes mellitus [28]. In vitro researches showed that these polymorphisms lead to 
higher rate of TNF gene transcription and thus higher level of TNF production. 
Despite extensive research performed the last decades, there are still 
unexplored areas and unanswered questions. Thus, the implication of TNF-α promoter 
polymorphisms in the initiation and progression of inflammatory cascade in diabetic 
nephropathy [12, 21, 25, 29, 30] remains controversial. 
In order to achieve integrated and reliable conclusions, meta-analyses are 
required. In the present meta-analysis we aim to review candidate-genome associated 
studies for TNF-a 308 G/A polymorphism in correlation with diabetic nephropathy 
risk. 
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3. Methods 
 
 
 
3.1  Identification and Eligibility of relevant studies 
 
An electronic search of the Pubmed literature was conducted until August 
2015 in order to investigate the association between TNF-a 308 G/A polymorphism 
and diabetic nephropathy risk. The search terms that were used in multiple 
combinations included: “polymorphism” or “mutation” or “allele” or “SNP”, “TNF” 
or “tumor necrosis factor” and “diabetic nephropathy” or “nephropathy” or 
“diabetes”. Only articles in English language were recorded. 
Studies that were eligible for inclusion in the meta-analysis were candidate-
gene association studies (GAS) that determined the distribution of TNF-a 308 G/A 
polymorphism in subjects with diabetic nephropathy and in a. diseased controls 
(subjects with diabetes mellitus but not nephropathy or subjects with other primary 
cause or nephropathy and no diabetes mellitus) or in b. healthy controls. 
Cases with diabetes mellitus were considered as suffering from diabetic 
nephropathy on the basis of persistent albuminuria or microalbuminuria with or 
without chronic renal insufficiency and in the absence of nondiabetic renal disease or 
patients with end-stage renal disease. 
The diseased control group consisted of subjects with diabetes and free of diabetic 
kidney disease. 
Only studies in human subjects that used validated genotyping methods were 
considered. Case reports, editorials and review articles were also excluded. The 
retrieved studies were read in their entirety to assess their appropriateness for 
inclusion in the meta-analysis. All references cited in the studies were also reviewed 
in order to identify additional published work that was not indexed by the Pubmed 
database. 
 
 
 
 
 3.2 Data extraction 
 
The following information was extracted from each study: First author’s last name, 
Journal, Year of Publication, Country of origin, Ethnicity, demographics, clinical 
characteristics, Sample Size, Type of DM, Genotype number in cases and controls. 
 
 
 
3.3       Statistical Analysis 
 
The TNF 308G/A genotypes include GA, GG and AA. The above genetic 
models were performed: (1) additive: AA versus GG, (2) co-dominant: GG+AA 
versus GA, (3) dominant: GA+AA versus GG and (4) recessive: AA versus AG+GG 
respectively [31]. 
The strength of the association between TNF-a 308 G/A polymorphism and 
diabetic nephropathy was indicated as a pooled Odds Ratio (OR) with the 
corresponding 95% Confidence Interval (95% CI). The statistical significance of 
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summary OR was determined using a Z-test. The heterogeneity between studies was 
assessed by a χ2-based Q statistic and a p value of <0.10 was considered statistically 
significant. Heterogeneity was quantified with the I
2
 metric [32]. Pooled OR was 
analyzed by a fixed-effects (FE) model (Mantel-Haenszel method) or a random-
effects (RE) model (DerSimonian and Laird method) according to heterogeneity [33, 
34]. Finally the generalized OR was calculated [35]. 
The meta-analysis consisted of the main (overall) analysis, which included all 
available data. Further efforts were conducted on the subgroup analyses according to 
ethnicity defined as Asian and Caucasian and the type of DM (DM1 or DM2). 
Sensitivity analysis examined the effect of excluding specific studies that did 
not follow the Hardy-Weinberg equilibrium (HWE) test [36]. 
All Statistical Test were performed using Comprehension Meta Analysis V3, 
MedCal 15.8 and ORGGASMA [35] (available at http://biomath.med.uth.gr) 
software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:30 EET - 137.108.70.7
9 
 
4. Results 
 
 
 
4.1  Eligible Studies and study characteristics 
 
The literature review identified 11 candidate-genome associated studies in 
Pubmed. The full articles of the retrieved studies were read to assess their 
appropriateness for meta-analysis according to the inclusion criteria. Data from 9 
articles that investigated the association between TNF-a 308G/A polymorphism and 
the risk of DN met the inclusion criteria [37-45]. One study was excluded due to 
incomplete data on genotype frequencies [46]. Finally, one study investigated the 
association of TNF-a 308 G/A polymorphism between subjects with DM that 
presented with acute kidney injury while been hospitalized in an ICU. In those 
subjects DN could lurk but the study was also excluded because it did not met the 
criteria of a safe diagnosis of DN [47]. Figure 1 represents a flowchart of retrieved 
studies and studies excluded. The studies were published between 2004 and 2015. 
 
 
Figure 1.  Flow-chart of the retrieved studies 
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A list of details abstracted from the studies included in the meta-analysis and 
are provides in Table 1, 2 and 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Characteristics of Cases of the Studies considered in the meta-analysis        
Authors Ethnicity Selection Criteria 
DM 
type 
n of M 
(%) 
Age 
(yr) 
DM 
duration 
        
Babel et al Caucasian renal failure or HD, diagnosis by renal biopsy 2 27(61%) 47,5±7,8 ND 
Bucan et al Caucasian microalbuminuria or proteinuria 1     21,4±6 
Buraczynska Caucasian DN on peritoneal dialysis 1+2 19(51.4%) 55,7(22-±78) ND 
Lindholm et al Caucasian DN due to DM1 1+2 ND ND >20 years 
Manchanda et al Asian DN with s.creat >4mg/dL, under HD for at least 3 months ND ND ND ND 
Peng et al Asian DN ND ND ND ND 
Prasad et al Asian DM2 with s.creat > 3mg/dL, AER> 200mg/L and DR 2 ND ND >2 years 
Sikka et al. Asian DN in HD 2 ND ND 13,15±7,65 
Singh et al Asian CRF/ ESRD due to DM ND ND ND ND 
Table 2. Characteristics of the Controls of  Studies considered in the meta-analysis  
Authors Ethnicity Status 
DM 
type 
n of M 
(%) Age (yr) 
DM 
duration 
              
Babel et al Caucasian healthy 2 52(43%) 41±8,4 NA 
Bucan et al Caucasian diseased 1     12,8±8,9 
Buraczynska Caucasian diseased (patients in HD with other primary renal diseases) 1+2 32(55.2%) 52,8(23-78) ND 
    or healthy   69(60%) 46,64(21-61) ND 
Lindholm et al Caucasian healthy 1+2 ND ND NA 
Manchanda et al Asian healthy ND 102)56,6%) 34,96±11,3 NA 
Peng et al Asian healthy ND ND ND NA 
Prasad et al Asian diseased (DM2 > 10 years, normoalbuminuria, AER< 20mg/L) 2 ND ND 17,07 ±6,69 
Sikka et al. Asian healthy 2 ND ND NA 
    diseased   ND ND 7,27±6,75 
Singh et al Asian healthy ND ND ND NA 
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Four studies involved cases with T2DM and two with both T1DM and T2DM. 
The remaining studies did not specify the type of DM. In five studies the controls 
were healthy subjects while only in two studies the controls were diseased. In the 
remaining studies there were two control groups, one healthy and one diseased. 
Studies were conducted in two populations: Asians and Caucasians. 
 
 
 
 
 
4.2 Summary statistics 
 
Since the control groups in the nine studies were of two categories, two meta-
analyses were performed. The first consisted of healthy controls subjects and included seven 
studies and the second consisted of diseased subjects and included four studies. Data from the 
two studies with both healthy and diseased controls were extracted and those studies 
participated in both meta-analyses. 
In four studies [38-40, 44], the distribution of genotypes in control groups was not in 
HWE (P<0.05), indicating genotyping errors and/ or population stratification, therefore, a 
sensitivity analysis was preformed excluding those studies. 
 
 
 
 
 
 
4.2.1  Meta-analysis A: Healthy Controls 
 
In this meta-analysis, seven studies were included (Table 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Meta-analysis A (healthy controls): Studies participating 
Authors Ethnicity Cases Controls HWE p value 
     Babel et al. Caucasian 44 113 0,858 
Buraczynska et al. Caucasian 37 115 0,065 
Lindholm et al. Caucasian 527 528 0 
Manchanda et al. Asian 23 180 0 
Peng et al. Asian 86 94 0,056 
Sikka et al. Asian 137 203 0,31 
Singh et al Asian 49 66 0 
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Overall, for the TNF-a 308 G/A polymorphism and its relationship to DN, the 
dominant model showed a marginally significant association (OR= 1.449, 95% CI: 0.797 – 
2.635), indicating that A carriers have 45% more chance of developing diabetic nephropathy. 
The heterogeneity between studies was significant (PQ<0.01, I
2
=86.78%) as it is shown in 
Figure 2.  
 
 
 
 
Figure 2.  Meta-analysis A (healthy controls): overall analysis 
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The generalized OR is 1.482 (95% CI: 0.817 – 2.69) but it is not significant (Figure 3). 
 
 
 
Figure 3.    Meta-analysis A (healthy controls): ORG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.1.1. Sensitivity Analysis 
 
 
 
Sensitivity analysis performed after the exclusion of the studies that were not into 
HWE (Figure 4). According to the results, the recessive model showed significant association 
(OR= 2.701, 95% CI: 1.089 – 6.701), indicating that AA genotype has better chance of 
developing diabetic nephropathy, while the heterogeneity between studies was not statistically 
significant (PQ=0.123, I
2
=48%). Thus, data from publications not in the HWE may have a 
significant influence on the overall result. 
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Figure 4.  Meta-analysis A (healthy controls): Sensitivity analysis 
 
 
 
 
4.2.1.2. Subgroup analysis 
 
 
Subgroup analysis showed significant association between the polymorphism and 
diabetic nephropathy  in both additive and recessive models (OR=6.838, 95% CI: 1.494 – 
31.298 and OR=1.888, 95% CI: 1.274 – 2.798 respectively) for Asians (Figure 5) but no 
significance observed in Caucasians (Figure 6). 
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Figure 5.  Meta-analysis A (healthy controls): Subgroup analysis - Asians 
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Figure 6.    Meta-analysis A (healthy controls): Subgroup analysis - Caucasians 
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4.2.2. Meta-analysis B: Diseased Controls 
 
 
 
In this meta-analysis, four studies were included (Table 4). 
 
 
 
 
Table 4. Meta-analysis B (diseased controls) : Studies participating 
Authors Ethnicity Patient Controls HWE p-value 
     Bucan et al. Caucasian 14 33 0,007 
Buraczynska et al. Caucasian 37 58 0,33 
Prasad et al. Asian 196 224 0,336 
Sikka et al. Asian 137 196 0,408 
 
 
 
 
 
 
Overall, for the TNF-a 308 G/A polymorphism and its relationship to DN no 
significant association was observed (Figure 7). The generalized OR is 0.213 (95% CI: 0.103 
– 4.38) but it is not statistically significant (Figure 8). 
Sensitivity analysis performed after the exclusion of the studies that were not into 
HWE. According to the results, no significant association between TNF-a 308 G/A 
polymorphism and DN was observed (Figure 9). 
Subgroup analysis was not performed because of the small number of studies thus, 
definite conclusions cannot be drawn. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:30 EET - 137.108.70.7
19 
 
 
Figure 7.   Meta-analysis B (diseased controls): overall analysis 
 
 
 
 
 
 
Figure 8.     Meta-analysis B (diseased controls): ORG 
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Figure 9.   Meta-analysis B (diseased controls): Sensitivity analysis 
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5. Conclusions 
 
It has been observed that some diabetic patients that experience long-term 
hyperglycemia develop nephropathy while others do not [48] and this phenomenon is 
inexplicable. Environmental exposure is only one side of the problem and this is why 
genetic background is under the microscope. Several valid explanations for this 
situation have been proposed but the most striking cause lies in the multifactorial and 
highly redundant nature of the molecular pathways of this disease. 
During the past years, the role and association of TNF-a variation has raised 
attention. While several studies have been reported [49, 50], the results remain 
inconclusive due to parameters such as difference in ethnicity, age, sex and lifestyle. 
These studies were not powerful enough to provide us with reliable results. Therefore, 
a meta-analysis is needed in order to give a more conclusive answer. 
The two meta-analyses previously performed, examined the TNF-a 308 G/A 
polymorphism and its relationship to susceptibility for diabetic nephropathy. In total, 
the meta-analyses involved 9 candidate genome associated studies for diabetic 
nephropathy which provided 1113/1810 cases /controls. In this study, the effects of 
the additive, co-dominant, dominant and recessive models as well as the generalized 
odds ratio were estimated. In addition the consistency of genetic effects across 
populations from different ethnicities were investigated [51] through subgroup 
analysis by rage.  No other subgroup analysis was able to be produced (i.e. subgroup 
analysis by type of diabetes mellitus or gender) due to missing data. Sensitivity 
analysis for studies not in HWE was also performed. 
In overall analyses and subgroup analyses, the testing of associations was 
based on different amount of information. Therefore, any comparisons between the 
effect sizes should be interpreted with caution. 
These meta-analyses had some limitations. First, the results may be applicable 
to two ethnic groups, as the case controlled studies used involved Caucasian and 
Asian populations. Further studies are required to investigate the association in other 
populations. Second, gender specific subgroup analysis should have been carried out 
since diabetic nephropathy is more frequent in men [3], but the original data were 
found to be insufficient. Third, the diagnostic criteria of diabetic nephropathy varied 
while, in some studies, were not precisely described. This may be a cause of potential 
bias. Fourth, in two articles [45, 46], accurate numbers on genotypes distributions 
were not accessible. As a result, related data were not included in analyses. Fifth, in 
one study [47], subjects participating may introduce themselves to diabetic 
nephropathy, but the study was excluded since it was not defined whether there was a 
diagnosis or not. 
The fact that non-English, nonindexed and nonpublished studies literature 
were not reviewed may introduce some bias [52]. Subsequently studies that 
demonstrate statistically significant results are more likely to be published in contrast 
with studies presenting negative finding, especially in English language indexed 
journal. 
The results suggest that the TNF-a 308 G/A polymorphism may be associated 
with an increased diabetic nephropathy risk in Asians but not in Caucasians. Large-
scale genome associated studies are required to confirm these findings. 
These outcomes indicate that the pathogenesis of DM and its related 
complications is rather complex. Correlations between genes single nucleotide 
polymorphisms, ethnicity, environmental and other factors may potentially influence 
such diseases. 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:30 EET - 137.108.70.7
22 
 
6. References 
 
 
1. Cooper, M.E., Diabetes: treating diabetic nephropathy-still an unresolved 
issue. Nat Rev Endocrinol, 2012. 8(9): p. 515-6. 
2. Tuttle, K.R., et al., Diabetic kidney disease: a report from an ADA Consensus 
Conference. Diabetes Care, 2014. 37(10): p. 2864-83. 
3. Mollsten, A., et al., A polymorphism in the angiotensin II type 1 receptor gene 
has different effects on the risk of diabetic nephropathy in men and women. 
Mol Genet Metab, 2011. 103(1): p. 66-70. 
4. Burden, A.C., et al., Increased incidence of end-stage renal failure secondary 
to diabetes mellitus in Asian ethnic groups in the United Kingdom. Diabet 
Med, 1992. 9(7): p. 641-5. 
5. Cowie, C.C., et al., Disparities in incidence of diabetic end-stage renal 
disease according to race and type of diabetes. N Engl J Med, 1989. 321(16): 
p. 1074-9. 
6. Parving, H.H. and E. Hommel, Prognosis in diabetic nephropathy. BMJ, 
1989. 299(6693): p. 230-3. 
7. Wolf, G., New insights into the pathophysiology of diabetic nephropathy: from 
haemodynamics to molecular pathology. Eur J Clin Invest, 2004. 34(12): p. 
785-96. 
8. Martini, S., et al., Defining human diabetic nephropathy on the molecular 
level: integration of transcriptomic profiles with biological knowledge. Rev 
Endocr Metab Disord, 2008. 9(4): p. 267-74. 
9. Hasegawa, G., et al., Possible role of tumor necrosis factor and interleukin-1 
in the development of diabetic nephropathy. Kidney Int, 1991. 40(6): p. 1007-
12. 
10. Noronha, I.L., et al., Cytokines and growth factors in renal disease. Nephrol 
Dial Transplant, 1995. 10(6): p. 775-86. 
11. Navarro-Gonzalez, J.F. and C. Mora-Fernandez, The role of inflammatory 
cytokines in diabetic nephropathy. J Am Soc Nephrol, 2008. 19(3): p. 433-42. 
12. Navarro, J.F., et al., Inflammatory parameters are independently associated 
with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis, 2003. 
42(1): p. 53-61. 
13. Moriwaki, Y., et al., Elevated levels of interleukin-18 and tumor necrosis 
factor-alpha in serum of patients with type 2 diabetes mellitus: relationship 
with diabetic nephropathy. Metabolism, 2003. 52(5): p. 605-8. 
14. Hamaguchi, K., et al., Analysis of tumor necrosis factor-alpha promoter 
polymorphism in type 1 diabetes: HLA-B and -DRB1 alleles are primarily 
associated with the disease in Japanese. Tissue Antigens, 2000. 55(1): p. 10-6. 
15. Sugimoto, H., et al., Advanced glycation end products-cytokine-nitric oxide 
sequence pathway in the development of diabetic nephropathy: 
aminoguanidine ameliorates the overexpression of tumour necrosis factor-
alpha and inducible nitric oxide synthase in diabetic rat glomeruli. 
Diabetologia, 1999. 42(7): p. 878-86. 
16. Jevnikar, A.M., et al., Stimulated kidney tubular epithelial cells express 
membrane associated and secreted TNF alpha. Kidney Int, 1991. 40(2): p. 
203-11. 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:30 EET - 137.108.70.7
23 
 
17. Dong, X., et al., Resident dendritic cells are the predominant TNF-secreting 
cell in early renal ischemia-reperfusion injury. Kidney Int, 2007. 71(7): p. 
619-28. 
18. Navarro-Gonzalez, J.F., et al., Inflammatory molecules and pathways in the 
pathogenesis of diabetic nephropathy. Nat Rev Nephrol, 2011. 7(6): p. 327-
40. 
19. Navarro, J.F., et al., Urinary tumour necrosis factor-alpha excretion 
independently correlates with clinical markers of glomerular and 
tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant, 
2006. 21(12): p. 3428-34. 
20. Navarro, J.F., et al., Renal pro-inflammatory cytokine gene expression in 
diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and 
pentoxifylline administration. Am J Nephrol, 2006. 26(6): p. 562-70. 
21. Navarro, J.F., et al., Tumor necrosis factor-alpha gene expression in diabetic 
nephropathy: relationship with urinary albumin excretion and effect of 
angiotensin-converting enzyme inhibition. Kidney Int Suppl, 2005(99): p. S98-
102. 
22. DiPetrillo, K. and F.A. Gesek, Pentoxifylline ameliorates renal tumor necrosis 
factor expression, sodium retention, and renal hypertrophy in diabetic rats. 
Am J Nephrol, 2004. 24(3): p. 352-9. 
23. Baud, L., et al., Tumor necrosis factor stimulates prostaglandin production 
and cyclic AMP levels in rat cultured mesangial cells. FEBS Lett, 1988. 
239(1): p. 50-4. 
24. Rivero, A., et al., Pathogenic perspectives for the role of inflammation in 
diabetic nephropathy. Clin Sci (Lond), 2009. 116(6): p. 479-92. 
25. Navarro, J.F., et al., Influence of renal involvement on peripheral blood 
mononuclear cell expression behaviour of tumour necrosis factor-alpha and 
interleukin-6 in type 2 diabetic patients. Nephrol Dial Transplant, 2008. 23(3): 
p. 919-26. 
26. Pociot, F., et al., No independent association between a tumor necrosis factor-
alpha promotor region polymorphism and insulin-dependent diabetes mellitus. 
Eur J Immunol, 1993. 23(11): p. 3050-3. 
27. Chang, W.T., et al., The -308G/A of Tumor Necrosis Factor (TNF)-alpha and 
825C/T of Guanidine Nucleotide Binding Protein 3 (GNB3) are associated 
with the onset of acute myocardial infarction and obesity in Taiwan. Int J Mol 
Sci, 2012. 13(2): p. 1846-57. 
28. Guzman-Flores, J.M., et al., Association analysis between -308G/A and -
238G/A TNF-alpha gene promoter polymorphisms and insulin resistance in 
Mexican women with gestational diabetes mellitus. J Investig Med, 2013. 
61(2): p. 265-9. 
29. Nakamura, T., et al., mRNA expression of growth factors in glomeruli from 
diabetic rats. Diabetes, 1993. 42(3): p. 450-6. 
30. Lin, J., et al., Lipid and inflammatory biomarkers and kidney function decline 
in type 2 diabetes. Diabetologia, 2010. 53(2): p. 263-7. 
31. Minelli, C., et al., The choice of a genetic model in the meta-analysis of 
molecular association studies. Int J Epidemiol, 2005. 34(6): p. 1319-28. 
32. Higgins, J.P. and S.G. Thompson, Quantifying heterogeneity in a meta-
analysis. Stat Med, 2002. 21(11): p. 1539-58. 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:30 EET - 137.108.70.7
24 
 
33. Zintzaras, E. and J. Lau, Synthesis of genetic association studies for pertinent 
gene-disease associations requires appropriate methodological and statistical 
approaches. J Clin Epidemiol, 2008. 61(7): p. 634-45. 
34. DerSimonian, R. and N. Laird, Meta-analysis in clinical trials. Control Clin 
Trials, 1986. 7(3): p. 177-88. 
35. Zintzaras, E., The generalized odds ratio as a measure of genetic risk effect in 
the analysis and meta-analysis of association studies. Stat Appl Genet Mol 
Biol, 2010. 9: p. Article21. 
36. Minelli, C., et al., How should we use information about HWE in the meta-
analyses of genetic association studies? Int J Epidemiol, 2008. 37(1): p. 136-
46. 
37. Babel, N., et al., Predictive value of cytokine gene polymorphisms for the 
development of end-stage renal disease. J Nephrol, 2006. 19(6): p. 802-7. 
38. Bucan, K., et al., Retinopathy and nephropathy in type 1 diabetic patients--
association with polymorphysms of vitamin D-receptor, TNF, Neuro-D and 
IL-1 receptor 1 genes. Coll Antropol, 2009. 33 Suppl 2: p. 99-105. 
39. Lindholm, E., et al., Association between LTA, TNF and AGER 
polymorphisms and late diabetic complications. PLoS One, 2008. 3(6): p. 
e2546. 
40. Manchanda, P.K., et al., Correlation between a gene polymorphism of tumor 
necrosis factor-alpha (G/A) and end-stage renal disease: a pilot study from 
north India. Clin Chim Acta, 2006. 370(1-2): p. 152-7. 
41. Peng, Y. and L.J. Li, TNF-alpha-308G/A polymorphism associated with TNF-
alpha protein expression in patients with diabetic nephropathy. Int J Clin Exp 
Pathol, 2015. 8(3): p. 3127-31. 
42. Prasad, P., et al., Association of TGFbeta1, TNFalpha, CCR2 and CCR5 gene 
polymorphisms in type-2 diabetes and renal insufficiency among Asian 
Indians. BMC Med Genet, 2007. 8: p. 20. 
43. Sikka, R., et al., TNF-alpha (g.-308 G > A) and ADIPOQ (g. + 45 T > G) 
gene polymorphisms in type 2 diabetes and microvascular complications in 
the region of Punjab (North-West India). Curr Eye Res, 2014. 39(10): p. 1042-
51. 
44. Singh, K., et al., Association of tumour necrosis factor-alpha polymorphism in 
patients with end stage renal disease. Nephrology (Carlton), 2015. 20(6): p. 
387-91. 
45. Wang, Y., et al., Association between tumour necrosis factor-alpha G-308A 
polymorphism and risk of nephropathy in obese Chinese type 2 diabetic 
patients. Nephrol Dial Transplant, 2005. 20(12): p. 2733-8. 
46. Krayenbuehl, P.A., et al., TNF-alpha -308G>A polymorphism modulates 
cytokine serum concentrations and macrovascular complications in diabetic 
patients on aspirin. Exp Clin Endocrinol Diabetes, 2007. 115(5): p. 322-6. 
47. Dalboni, M.A., et al., Tumour necrosis factor-alpha plus interleukin-10 low 
producer phenotype predicts acute kidney injury and death in intensive care 
unit patients. Clin Exp Immunol, 2013. 173(2): p. 242-9. 
48. Krolewski, A.S., et al., The changing natural history of nephropathy in type I 
diabetes. Am J Med, 1985. 78(5): p. 785-94. 
49. Lee, S.H., et al., Genetics of diabetic nephropathy in type 2 DM: candidate 
gene analysis for the pathogenic role of inflammation. Nephrology (Carlton), 
2005. 10 Suppl: p. S32-6. 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:30 EET - 137.108.70.7
25 
 
50. Buraczynska, K., et al., Genetic determination of TNF and myeloperoxidase 
production in dialyzed patients with diabetic nephropathy. Ren Fail, 2004. 
26(6): p. 633-9. 
51. Zintzaras, E. and J. Lau, Trends in meta-analysis of genetic association 
studies. J Hum Genet, 2008. 53(1): p. 1-9. 
52. Egger, M., et al., Language bias in randomised controlled trials published in 
English and German. Lancet, 1997. 350(9074): p. 326-9. 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:30 EET - 137.108.70.7
